| P50 | author | Angela Gronenborn | Q19609591 |
| P2093 | author name string | G M Clore | |
| | I T Weber | |
| | J Tözsér | |
| | J M Louis | |
| P2860 | cites work | Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes | Q24673104 |
| | Structural and kinetic analysis of drug resistant mutants of HIV-1 protease | Q27619254 |
| | Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors | Q27731528 |
| | Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced amide inhibitor and comparison with HIV-1 protease structures | Q27732012 |
| | Three-dimensional structures of HIV-1 and SIV protease product complexes | Q27733521 |
| | Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors | Q27734856 |
| | Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates | Q27747736 |
| | Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease | Q27748879 |
| | Structural basis for specificity of retroviral proteases | Q27749013 |
| | On the size of the active site in proteases. I. Papain | Q27860826 |
| | Proteolytic cleavage of microtubule-associated proteins by retroviral proteinases | Q28254374 |
| | Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor | Q28369516 |
| | Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors | Q28378860 |
| | Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators | Q29547281 |
| | Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection | Q29547852 |
| | Viral dynamics in human immunodeficiency virus type 1 infection | Q29547908 |
| | 1H, 13C and 15N random coil NMR chemical shifts of the common amino acids. I. Investigations of nearest-neighbor effects | Q29616506 |
| | Inhibitors of HIV-1 protease: a major success of structure-assisted drug design | Q32059371 |
| | Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins | Q34098983 |
| | A structural model for the retroviral proteases. | Q34173510 |
| | Predicting human immunodeficiency virus protease cleavage sites in proteins by a discriminant function method | Q34379398 |
| | Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments | Q34618267 |
| | The HIV-1 protease as a therapeutic target for AIDS | Q35898324 |
| | Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. | Q36650046 |
| | Molecular characterization of gag proteins from simian immunodeficiency virus (SIVMne). | Q36877852 |
| | Retroviral proteinases | Q37950642 |
| | Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance | Q38299527 |
| | Autoprocessing of the HIV-1 protease using purified wild-type and mutated fusion proteins expressed at high levels in Escherichia coli | Q38334320 |
| | Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. | Q38357781 |
| | Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. | Q39550343 |
| | Resistance to human immunodeficiency virus type 1 protease inhibitors. | Q39559316 |
| | Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. | Q39579408 |
| | Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors | Q39780160 |
| | Standardized and simplified nomenclature for proteins common to all retroviruses | Q40127929 |
| | Subsite preferences of retroviral proteinases | Q40591356 |
| | Specificity of retroviral proteases: an analysis of viral and nonviral protein substrates | Q40591362 |
| | Structure-based inhibitors of HIV-1 protease | Q40835286 |
| | The HIV protease and therapies for AIDS. | Q40911164 |
| | Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles | Q41564861 |
| | Peptide substrates and inhibitors of the HIV-1 protease | Q42195484 |
| | Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure | Q42277211 |
| | Ordered accumulation of mutations in HIV protease confers resistance to ritonavir | Q42555782 |
| | Secondary structure and signal assignments of human-immunodeficiency-virus-1 protease complexed to a novel, structure-based inhibitor | Q42612484 |
| | Sequence-specific resonance assignments of the 1H-NMR spectra and structural characterization in solution of the HIV-1 transframe protein p6. | Q42631042 |
| | Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism | Q43640338 |
| | Substitution mutations of the highly conserved arginine 87 of HIV-1 protease result in loss of proteolytic activity | Q43656708 |
| | Substitutions at the P2' site of gag p17-p24 affect cleavage efficiency by HIV-1 protease | Q43872359 |
| | Kinetic and modeling studies of S3-S3' subsites of HIV proteinases | Q44403208 |
| | Different requirements for productive interaction between the active site of HIV-1 proteinase and substrates containing -hydrophobic*hydrophobic- or -aromatic*pro- cleavage sites | Q44968894 |
| | Studies on the role of the S4 substrate binding site of HIV proteinases | Q45058440 |
| | The gag precursor contains a specific HIV-1 protease cleavage site between the NC (P7) and P1 proteins | Q45183042 |
| | Characterization of human immunodeficiency virus type-1 (HIV-1) particles that express protease-reverse transcriptase fusion proteins | Q45752917 |
| | Activity of tethered human immunodeficiency virus 1 protease containing mutations in the flap region of one subunit | Q45764299 |
| | Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex | Q45765743 |
| | Influence of flanking sequences on the dimer stability of human immunodeficiency virus type 1 protease | Q45767677 |
| | Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants | Q45770160 |
| | Comparative studies on the substrate specificity of avian myeloblastosis virus proteinase and lentiviral proteinases | Q45770708 |
| | Human immunodeficiency virus, type 1 protease substrate specificity is limited by interactions between substrate amino acids bound in adjacent enzyme subsites | Q45771086 |
| | Proteolytic processing mechanisms of a miniprecursor of the aspartic protease of human immunodeficiency virus type 1. | Q45779651 |
| | A possible regulation of negative factor (Nef) activity of human immunodeficiency virus type 1 by the viral protease. | Q45780734 |
| | Substrate-dependent mechanisms in the catalysis of human immunodeficiency virus protease | Q45780866 |
| | Genetic locus, primary structure, and chemical synthesis of human immunodeficiency virus protease | Q45834168 |
| | Sub-site preferences of the aspartic proteinase from the human immunodeficiency virus, HIV-1. | Q45850256 |
| | Characterization of ribosomal frameshifting in HIV-1 gag-pol expression | Q46573916 |
| | Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients | Q46882076 |
| | Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. | Q46964850 |
| | Energy calculations and analysis of HIV-1 protease-inhibitor crystal structures | Q47633804 |
| | Proteolytic processing of HIV-1 protease precursor, kinetics and mechanism | Q47940296 |
| | A transient precursor of the HIV-1 protease. Isolation, characterization, and kinetics of maturation. | Q52202674 |
| | In situ processing of a retroviral nucleocapsid protein by the viral proteinase. | Q53497333 |
| | The HIV-1 protease as enzyme and substrate: mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties. | Q54197412 |
| | Intrinsic activity of precursor forms of HIV-1 proteinase | Q54667327 |
| | Fidelity of HIV-1 reverse transcriptase copying RNA in vitro | Q54683510 |
| | Hydrolysis of synthetic chromogenic substrates by HIV-1 and HIV-2 proteinases | Q62396129 |
| | Inhibition of aspartic proteinases by synthetic peptides derived from the propart region of human prorenin | Q67737644 |
| | Comparative analysis of the sequences and structures of HIV-1 and HIV-2 proteases | Q68051379 |
| | The mechanism of action of aspartic proteases involves 'push-pull' catalysis | Q70182509 |
| | HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins | Q70219564 |
| | Studies on the symmetry and sequence context dependence of the HIV-1 proteinase specificity | Q73456257 |
| | Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate | Q77349901 |
| | ??? | Q57904706 |
| P921 | main subject | drug resistance | Q12147416 |
| P304 | page(s) | 111-146 | |
| P577 | publication date | 2000-01-01 | |
| P1433 | published in | Advances in Pharmacology | Q15753809 |
| P1476 | title | HIV-1 protease: maturation, enzyme specificity, and drug resistance | |
| P478 | volume | 49 | |